Post by glasgowalliance on Jan 18, 2005 0:26:49 GMT
A major clinical trial which could provide a breakthrough in the treatment of Alzheimer's disease was launched today.
Around 400 patients from across the UK who have been diagnosed with the condition will take part in the £1.4million study.
It is hoped that a drug will be able to dissolve tangles of proteins in the brain which correlate with dementia, the most common form of the
disease.
The drug has been developed by Aberdeen University spin-off company TauRX Therapeutics Pte, headed by Professor Claude Wischik.
Prof Wischik, who has spent 20 years researching Alzheimer's disease, said: "Our drug is different to existing treatments, some of which mask the progression of the disease.
"We want to see if it can modify the course of the disease following promising results in laboratory tests."
Patients taking part in the study must have a clinical diagnosis of Alzheimer's disease and contact with another person who can monitor the effects of the medication.
They will be given a brain scan and will be assessed by their local study centre on eight occasions. A major clinical trial which could provide a breakthrough in the treatment of Alzheimer's disease was launched today.
Around 400 patients from across the UK who have been diagnosed with the condition will take part in the £1.4million study.
It is hoped that a drug will be able to dissolve tangles of proteins in the brain which correlate with dementia, the most common form of the
disease.
The drug has been developed by Aberdeen University spin-off company TauRX Therapeutics Pte, headed by Professor Claude Wischik.
Prof Wischik, who has spent 20 years researching Alzheimer's disease, said: "Our drug is different to existing treatments, some of which mask the progression of the disease.
"We want to see if it can modify the course of the disease following promising results in laboratory tests."
Patients taking part in the study must have a clinical diagnosis of Alzheimer's disease and contact with another person who can monitor the effects of the medication.
They will be given a brain scan and will be assessed by their local study centre on eight occasions.
Around 400 patients from across the UK who have been diagnosed with the condition will take part in the £1.4million study.
It is hoped that a drug will be able to dissolve tangles of proteins in the brain which correlate with dementia, the most common form of the
disease.
The drug has been developed by Aberdeen University spin-off company TauRX Therapeutics Pte, headed by Professor Claude Wischik.
Prof Wischik, who has spent 20 years researching Alzheimer's disease, said: "Our drug is different to existing treatments, some of which mask the progression of the disease.
"We want to see if it can modify the course of the disease following promising results in laboratory tests."
Patients taking part in the study must have a clinical diagnosis of Alzheimer's disease and contact with another person who can monitor the effects of the medication.
They will be given a brain scan and will be assessed by their local study centre on eight occasions. A major clinical trial which could provide a breakthrough in the treatment of Alzheimer's disease was launched today.
Around 400 patients from across the UK who have been diagnosed with the condition will take part in the £1.4million study.
It is hoped that a drug will be able to dissolve tangles of proteins in the brain which correlate with dementia, the most common form of the
disease.
The drug has been developed by Aberdeen University spin-off company TauRX Therapeutics Pte, headed by Professor Claude Wischik.
Prof Wischik, who has spent 20 years researching Alzheimer's disease, said: "Our drug is different to existing treatments, some of which mask the progression of the disease.
"We want to see if it can modify the course of the disease following promising results in laboratory tests."
Patients taking part in the study must have a clinical diagnosis of Alzheimer's disease and contact with another person who can monitor the effects of the medication.
They will be given a brain scan and will be assessed by their local study centre on eight occasions.
